Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Adv Healthc Mater ; 12(23): e2300376, 2023 09.
Artículo en Inglés | MEDLINE | ID: mdl-37161587

RESUMEN

Pulmonary inflammation is one of the most reported tissue inflammations in clinic. Successful suppression of inflammation is vital to prevent further inevitably fatal lung degeneration. Glucocorticoid hormone, such as methylprednisolone (MP), is the most applied strategy to control the inflammatory progression yet faces the challenge of systemic side effects caused by the requirement of large-dosage and frequent administration. Highly efficient delivery of MP specifically targeted to inflammatory lung sites may overcome this challenge. Therefore, the present study develops an inflammation-targeted biomimetic nanovehicle, which hybridizes the cell membrane of mesenchymal stem cell with liposome, named as MSCsome. This hybrid nanovehicle shows the ability of high targeting specificity toward inflamed lung cells, due to both the good lung endothelium penetration and the high uptake by inflamed lung cells. Consequently, a single-dose administration of this MP-loaded hybrid nanovehicle achieves a prominent treatment of lipopolysaccharide-induced lung inflammation, and negligible treatment-induced side effects are observed. The present study provides a powerful inflammation-targeted nanovehicle using biomimetic strategy to solve the current challenges of targeted inflammation intervention.


Asunto(s)
Inflamación , Neumonía , Humanos , Inflamación/tratamiento farmacológico , Inflamación/metabolismo , Neumonía/tratamiento farmacológico , Neumonía/metabolismo , Metilprednisolona/metabolismo , Metilprednisolona/farmacología , Metilprednisolona/uso terapéutico , Pulmón/metabolismo , Liposomas/farmacología
2.
J Control Release ; 345: 292-305, 2022 05.
Artículo en Inglés | MEDLINE | ID: mdl-35314262

RESUMEN

Over millions of years, nature has created countless unique features frequently used in the manufacture of adhesive formulations for wound healing. The bioinspired adhesives could accommodate dynamic tissue movement with excellent biocompatibility to facilitate external and internal wound healing. In this review, we summarise two types of bioinspired adhesives used for wound healing, including chemical-rationale bioinspired adhesives, such as mussel-inspired injectable hydrogel and physical-rationale bioinspired adhesives, such as octopus-inspired adhesive patches. Herein, we mainly focus on fundamental design, multi-faceted bionic strategies and potential clinical utility in surgical wound closure, haemostasis and tissue regeneration. We discuss the feasibility of incorporating nature-inspired properties into formulation design to offer a new reference for the application of bioinspired wound dressings.


Asunto(s)
Adhesivos , Adhesivos Tisulares , Vendajes , Hidrogeles , Cicatrización de Heridas
3.
Biomaterials ; 312: 122742, 2025 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-39106821

RESUMEN

Hypertrophic scar (HS) tends to raised above skin level with high inflammatory microenvironment and excessive proliferation of myofibroblasts. The HS therapy remains challenging due to dense scar tissue which makes it hard to penetrate, and the side effects resulting from intralesional corticosteroid injection which is the mainstay treatment in clinic. Herein, bilayer microneedle patches combined with dexamethasone and colchicine (DC-MNs) with differential dual-release pattern is designed. Two drugs loaded in commercially available materials HA and PLGA, respectively. Specifically, after administration, outer layer rapidly releases the anti-inflammatory drug dexamethasone, which inhibits macrophage polarization to pro-inflammatory phenotype in scar tissue. Subsequently, inner layer degrades sustainedly, releasing antimicrotubular agent colchicine, which suppresses the overproliferation of myofibroblasts with extremely narrow therapeutic window, and inhibits the overexpression of collagen, as well as promotes the regular arrangement of collagen. Only applied once, DC-MNs directly delivered drugs to the scar tissue. Compared to traditional treatment regimen, DC-MNs significantly suppressed HS at lower dosage and frequency by differential dual-release design. Therefore, this study put forward the idea of integrated DC-MNs accompany the development of HS, providing a non-invasive, self-applicable, more efficient and secure strategy for treatment of HS.


Asunto(s)
Antiinflamatorios , Cicatriz Hipertrófica , Colchicina , Dexametasona , Miofibroblastos , Agujas , Cicatriz Hipertrófica/tratamiento farmacológico , Cicatriz Hipertrófica/patología , Animales , Miofibroblastos/efectos de los fármacos , Miofibroblastos/metabolismo , Dexametasona/farmacología , Dexametasona/administración & dosificación , Dexametasona/uso terapéutico , Antiinflamatorios/uso terapéutico , Antiinflamatorios/administración & dosificación , Antiinflamatorios/farmacología , Colchicina/farmacología , Colchicina/administración & dosificación , Ratones , Sistemas de Liberación de Medicamentos , Humanos , Copolímero de Ácido Poliláctico-Ácido Poliglicólico/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA